Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14300996 | 1.00 | L3MBTL1 (0.32) | L3MBTL1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL12420353 | 1.00 | L3MBTL1 (0.32) | L3MBTL1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL14010448 | 0.76 | SLC6A3 (0.42) | L3MBTL1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL21120312 | 0.76 | TDP1 (0.35) | L3MBTL1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL14275444 | 0.76 | TDP1 (0.35) | L3MBTL1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL23065774 | 0.76 | TDP1 (0.35) | L3MBTL1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL8219435 | 0.76 | CA2 (0.38) | POLB | |
| SCHEMBL14601332 | 0.76 | SLC6A3 (0.42) | L3MBTL1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL18653492 | 0.76 | SLC6A3 (0.42) | L3MBTL1GAAHSP90AA1MAPTGPR55 | |
| SCHEMBL3047902 | 0.75 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433243-B1 | NOVEL DERIVATIVES AND THEIR USE AS SELECTIVE INHIBITORS OF CASPASE-2 | INST NAT SANTE RECH MED (FR) | 2021-09-08 | — | — | EP | disclosed |
| US-10626144-B2 | Peptide derivatives and uses thereof | NOSOPHARM (FR) | 2020-04-21 | — | — | US | disclosed |
| WO-2019163958-A1 | DRUG COMPOSITE, MICELLE, AND PHARMACEUTICAL COMPOSITION | 公益財団法人川崎市産業振興財団 | 2019-08-29 | — | — | WO | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| US-20140135254-A1 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20120052097-A1 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | CERULEAN PHARMA INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626144-B2 | Peptide derivatives and uses thereof | VIP, IAPP, NGLY1 | L3MBTL1 1817/4885GAA 1526/4885HSP90AA1 1678/4885 |
| US-20120052097-A1 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | IAPP, PSAP, LNPEP | L3MBTL1 2017/4885GAA 194/4885HSP90AA1 640/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | L3MBTL1 1817/4885GAA 1526/4885HSP90AA1 1678/4885 |
| US-20140135254-A1 | THERAPEUTIC PEPTIDE-POLYMER CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS | IAPP, PSAP, LNPEP | L3MBTL1 2017/4885GAA 194/4885HSP90AA1 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.